Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC)

NCT01713296 is registered in ClinicalTrials.gov with Hellenic Oncology Research Group as lead sponsor.

NCT NCT01713296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01713296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Pazopanib, in Relapsed and Refractory Small Cell Lung Cancer (SCLC)
Lead sponsor
Hellenic Oncology Research Group
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
March 31, 2015
Enrollment
58 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

sclc